- Pages
- 3
- Published in
- Canada
Premium
Debiopharm Innovation Fund & Taiwania Capital Co-Lead Financing Round for Genialis to Propel Drug Development, Diagnostics and Treatment Planning Through Ai/Ml-Enabled Platform With A
2024
<Macro 'access_denied_modal'>
<Macro 'unauthorized_modal'>
Add to list
Citation
Debiopharm Group (Canada), 2024. Debiopharm Innovation Fund & Taiwania Capital Co-Lead Financing Round for Genialis to Propel Drug Development, Diagnostics and Treatment Planning Through Ai/Ml-Enabled Platform With A, Debiopharm Group (Canada).
Canada.
Retrieved from https://coilink.org/20.500.12592/4ahcy9k on 15 Nov 2024. COI: 20.500.12592/4ahcy9k.
Full-page Screenshot
